Cellphire

Cellphire Therapeutics, based in Rockville, MD, is dedicated to revolutionizing the treatment of hemorrhage by harnessing the unique biology of platelets. With a mission to prevent unnecessary deaths from controllable hemorrhage, the company focuses on developing innovative platelet therapeutics to meet the urgent needs of both military and civilian patients.

Currently, Cellphire is advancing its two differentiated products, CLPH-511 and FPH Thrombosomes, through Phase 2 clinical studies, aiming to address critical challenges posed by the limited shelf-life of conventional platelets. The company's vision is to enhance hemostatic efficacy and ensure that life-saving therapies are readily available to clinicians during emergencies.

Generated from the website